Surrozen, Inc/de Schedule 13G passive stakes

StemPoint Capital LP, along with affiliated entities, has reported beneficial ownership of 5.0% of Surrozen, Inc.'s common stock, primarily through warrant holdings.

5AM Ventures VII, L.P. and associated entities report a beneficial ownership of 7.8% in Surrozen, Inc., with potential for increased stake upon regulatory milestones.

TCG Crossover entities and Chen Yu have updated their Schedule 13G filing, reporting a combined beneficial ownership of 9.9% in Surrozen, Inc.

Venrock Healthcare Capital Partners and affiliates have filed a Schedule 13G/A reporting a 9.99% beneficial ownership stake in Surrozen, Inc. as of March 31, 2026.

5AM Ventures VII, L.P. and its affiliates report a 9.5% beneficial ownership stake in Surrozen, Inc. common stock.

Boxer Capital Management and associated entities have filed a Schedule 13G reporting a 6.67% beneficial ownership stake in Surrozen, Inc.

StemPoint Capital LP, along with affiliated entities and individuals, has reported a beneficial ownership of 4.5% in Surrozen, Inc. common stock.

Point72 Asset Management and Steven A. Cohen have reported a 5.4% beneficial ownership stake in Surrozen, Inc. common stock.

StemPoint Capital LP and affiliates have disclosed a 7.0% beneficial ownership stake in Surrozen, Inc., totaling 619,766 shares.

Stonepine Capital Management and its affiliates have reported a 3.6% beneficial ownership stake in Surrozen, Inc., totaling 316,289 shares.

Millennium Management and related entities have disclosed an 8.5% beneficial ownership stake in Surrozen, Inc. common stock as of December 31, 2025.

TCG Crossover Funds and Chen Yu disclose significant passive ownership in Surrozen, Inc., with Chen Yu holding an aggregate 11.4% stake.

Millennium Management and affiliated entities have reported a collective beneficial ownership of 6.6% in Surrozen, Inc. common stock.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 5.18% beneficial ownership stake in Surrozen, Inc. common stock.

StemPoint Capital LP and its affiliates have disclosed a significant 11.4% beneficial ownership stake in Surrozen, Inc., totaling over 1 million shares.

Driehaus Capital Management LLC has reported a 0.79% beneficial ownership stake in Surrozen, Inc. common stock as of June 30, 2025.

Stonepine Capital Management and related entities have disclosed a 5.8% beneficial ownership stake in Surrozen, Inc., totaling 508,687 shares.

RA Capital Management, along with its affiliates Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., has filed an amended Schedule 13G disclosing a beneficial ownership of 9.9% in Surrozen, Inc.'s common stock as of March 31, 2025.

Nantahala Capital Partners Limited Partnership has filed an amended Schedule 13G, reporting a 2.2% beneficial ownership stake in Surrozen, Inc. as of March 31, 2025.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. collectively reported a 1.9% beneficial ownership in Surrozen, Inc.'s common stock, totaling 166,666 shares, primarily through the exercise of warrants, as a passive investment.

StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have jointly filed an amendment to their Schedule 13G, disclosing a 15.8% beneficial ownership stake in Surrozen, Inc.'s common stock.

Driehaus Capital Management LLC has reported a 6.25% beneficial ownership stake in Surrozen, Inc.'s common stock as of March 31, 2025, according to a recent Schedule 13G filing.

Stonepine Capital Management, LLC and its affiliates have filed an amended Schedule 13G, reaffirming their beneficial ownership of 9.9% of Surrozen, Inc.'s common stock as of March 31, 2025.

Venrock Healthcare Capital Partners and affiliated entities have disclosed a 9.9% beneficial ownership stake in Surrozen, Inc. through a Schedule 13G filing, stemming from a recent private placement.

5AM Ventures VII, L.P., along with its general partner 5AM Partners VII, LLC, and managing members Andrew J. Schwab and Kush Parmar, have disclosed a 9.9% beneficial ownership stake in Surrozen, Inc. following a recent private placement.

AI Biotechnology LLC, along with its affiliates Access Industries Holdings LLC, Access Industries Management, LLC, and Len Blavatnik, has disclosed a 9.9% beneficial ownership stake in Surrozen, Inc. following a recent private placement and warrant exercises.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 9.99% in Surrozen, Inc.'s common stock as of December 31, 2024.

Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, has disclosed a passive beneficial ownership of 0.8% in Surrozen, Inc. as of December 31, 2024.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have jointly reported a 5.1% beneficial ownership stake in Surrozen, Inc.'s common stock as of December 31, 2024.

StemPoint Capital LP, along with its affiliates, has reported a beneficial ownership of 14.3% in Surrozen, Inc., totaling 485,231 shares, as detailed in an amended Schedule 13G filing.